Grace Therapeutics (NASDAQ:GRCE) Issues Quarterly Earnings Results

by · The Markets Daily

Grace Therapeutics (NASDAQ:GRCE – Get Free Report) announced its earnings results on Thursday. The company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.05), FiscalAI reports.

Grace Therapeutics Stock Down 0.6%

Shares of Grace Therapeutics stock traded down $0.02 during midday trading on Thursday, hitting $3.57. The company had a trading volume of 25,080 shares, compared to its average volume of 102,518. The company has a fifty day simple moving average of $3.54 and a 200 day simple moving average of $3.25. The stock has a market cap of $55.24 million, a price-to-earnings ratio of -5.76 and a beta of 0.76. Grace Therapeutics has a 12-month low of $1.75 and a 12-month high of $3.94.

Wall Street Analyst Weigh In

Several research firms recently commented on GRCE. Wall Street Zen upgraded shares of Grace Therapeutics to a “hold” rating in a research note on Friday, January 23rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Grace Therapeutics in a report on Thursday, January 22nd. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Grace Therapeutics has a consensus rating of “Hold” and a consensus target price of $12.00.

Check Out Our Latest Stock Analysis on GRCE

Institutional Investors Weigh In On Grace Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. SeaCrest Wealth Management LLC acquired a new position in shares of Grace Therapeutics in the 3rd quarter valued at $42,000. ADAR1 Capital Management LLC boosted its position in Grace Therapeutics by 98.4% in the third quarter. ADAR1 Capital Management LLC now owns 350,450 shares of the company’s stock valued at $1,043,000 after buying an additional 173,823 shares during the last quarter. Finally, Cerity Partners LLC purchased a new position in Grace Therapeutics during the 4th quarter worth approximately $1,463,000. 6.08% of the stock is currently owned by institutional investors and hedge funds.

About Grace Therapeutics

(Get Free Report)

Grace Therapeutics, Inc (NASDAQ: GRCE) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for rare genetic diseases. By employing a proprietary platform that integrates advanced molecular biology and biologic engineering, the company focuses on identifying and optimizing gene-based and protein-based candidates designed to address well-defined genetic drivers of disease.

The company’s pipeline features multiple preclinical programs targeting lysosomal storage disorders and other inherited metabolic conditions.

See Also